Carbidopa and Levodopa
Carbidopa and Levodopa is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Carbidopa and Levodopa; Generic name: CARBIDOPA AND LEVODOPA; Drug class: Aromatic Amino Acid [EPC].
| Brand name | Carbidopa and Levodopa |
|---|---|
| Generic name | CARBIDOPA AND LEVODOPA |
| Drug class | Aromatic Amino Acid [EPC] |
| Manufacturer | Amneal Pharmaceuticals NY LLC |
| Used for | INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. |
| Dosage | DOSAGE AND ADMINISTRATION Carbidopa and levodopa extended-release tablet contains carbidopa and levodopa in a 1:4 ratio as either the 50 mg/200 mg tablet or the 25 mg/100 mg tablet. The daily dosage of carbidopa and levodopa extended-release tablets must be determined by careful titration. Patients should be monitored closely during the dose adjustment period, particularly with regard to appearance or worsening of involuntary movements, dyskinesias or nausea. Carbidopa and levodopa extended-rele |
| Warnings | WARNINGS When patients are receiving levodopa without a decarboxylase inhibitor, levodopa must be discontinued at least twelve hours before carbidopa and levodopa extended-release tablets are started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy. Carbidopa and levodopa extended-release tablets should be substituted at a dosage that will provide approximately 25% of the previous levodopa dosage (see |
| Active ingredient(s) | CARBIDOPA HYDRATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0eb24333-3c11-41dd-888d-3a30d3c9d188 |